Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

TherapeuticsMD, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BOCA RATON, FLA.--(BUSINESS WIRE)--THERAPEUTICSMD, INC. (THERAPEUTICSMD OR THE COMPANY) (NASDAQ: TXMD), A COMPANY THAT OWNS RIGHTS TO PHARMACEUTICAL ROYALTIES, TODAY REPORTED FINANCIAL RESULTS FOR THE THREE MONTHS ENDED JUNE 30, 2025. SECOND QUARTER 2025 FINANCIAL RESULTS NET INCOME (LOSS) FROM CONTINUING OPERATIONS NET INCOME FROM CONTINUING OPERATIONS WAS $545 THOUSAND, OR $0.05 PER BASIC AND DILUTED COMMON SHARE, COMPARED TO A NET LOSS OF $(1.05) MILLION, OR $(0.09) PER BASIC AND DILUTED.

THERAPEUTICSMD ANNOUNCES SECOND QUARTER 2025 FINANCIAL RESULTS

BOCA RATON, FLA.--(BUSINESS WIRE)--THERAPEUTICSMD, INC. (THERAPEUTICSMD OR THE COMPANY) (NASDAQ: TXMD), A COMPANY THAT OWNS RIGHTS TO PHARMACEUTICAL ROYALTIES, TODAY REPORTED FINANCIAL RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2025. FIRST QUARTER 2025 FINANCIAL RESULTS NET LOSS FROM CONTINUING OPERATIONS NET LOSS FROM CONTINUING OPERATIONS WAS $(636) THOUSAND, OR $(0.06) PER BASIC AND DILUTED COMMON SHARE, A DECREASE OF $99 THOUSAND, COMPARED TO NET LOSS FROM CONTINUING OPERATIONS OF $(8.

THERAPEUTICSMD ANNOUNCES FIRST QUARTER 2025 FINANCIAL RESULTS

BOCA RATON, FLA.--(BUSINESS WIRE)--THERAPEUTICSMD, INC. (THERAPEUTICSMD OR THE COMPANY) (NASDAQ: TXMD), A COMPANY THAT OWNS RIGHTS TO PHARMACEUTICAL ROYALTIES, TODAY REPORTED FINANCIAL RESULTS FOR THE FULL YEAR ENDED DECEMBER 31, 2024. FULL YEAR 2024 FINANCIAL RESULTS NET LOSS FROM CONTINUING OPERATIONS NET LOSS FROM CONTINUING OPERATIONS WAS $(2.3) MILLION, OR $(0.20) PER BASIC AND DILUTED COMMON SHARE, A DECREASE OF $5.4 MILLION, COMPARED TO NET LOSS FROM CONTINUING OPERATIONS OF $(7.7) M.

THERAPEUTICSMD ANNOUNCES FULL YEAR 2024 FINANCIAL RESULTS

BOCA RATON, FLA.--(BUSINESS WIRE)--THERAPEUTICSMD, INC. (THERAPEUTICSMD OR THE COMPANY) (NASDAQ: TXMD), A COMPANY THAT OWNS RIGHTS TO PHARMACEUTICAL ROYALTIES, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2024. FIRST QUARTER 2024 FINANCIAL RESULTS NET INCOME (LOSS) FROM CONTINUING OPERATIONS NET LOSS FROM CONTINUING OPERATIONS WAS $(0.8) MILLION, OR $(0.07) PER BASIC AND DILUTED COMMON SHARE, COMPARED TO NET LOSS FROM CONTINUING OPERATIONS OF $(2.3) MILLION, OR $(0.

THERAPEUTICSMD ANNOUNCES FIRST QUARTER 2024 FINANCIAL RESULTS

BOCA RATON, FLA.--(BUSINESS WIRE)--THERAPEUTICSMD, INC. (THERAPEUTICSMD OR THE COMPANY) (NASDAQ: TXMD), A COMPANY THAT OWNS RIGHTS TO PHARMACEUTICAL ROYALTIES, TODAY REPORTED FINANCIAL RESULTS FOR THE FULL YEAR ENDED DECEMBER 31, 2023. WE CONTINUE TO EXPLORE A VARIETY OF STRATEGIC ALTERNATIVES WITH THE GOAL OF MAXIMIZING VALUE FOR OUR SHAREHOLDERS, STATED MARLAN D. WALKER, CHIEF EXECUTIVE OFFICER OF THERAPEUTICSMD. FULL YEAR 2023 FINANCIAL RESULTS NET INCOME (LOSS) FROM CONTINUING OPERATI.

THERAPEUTICSMD ANNOUNCES FULL YEAR 2023 FINANCIAL RESULTS

BOCA RATON, FLA.--(BUSINESS WIRE)--THERAPEUTICSMD, INC. (THERAPEUTICSMD OR THE COMPANY) (NASDAQ: TXMD), A COMPANY THAT OWNS RIGHTS TO PHARMACEUTICAL ROYALTIES, TODAY REPORTED FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2023. AS THE COMPANY CONTINUES ITS TRANSITION INTO A ROYALTY-BASED BUSINESS, WE REMAIN COMMITTED TO COST CONTROL TO MAXIMIZE THE VALUE OF OUR ROYALTY ASSETS, STATED MARLAN D. WALKER, CHIEF EXECUTIVE OFFICER OF THERAPEUTICSMD. THIRD QUARTER 2023 FINANCIAL RES.

THERAPEUTICSMD ANNOUNCES THIRD QUARTER 2023 FINANCIAL RESULTS

BOCA RATON, FLA.--(BUSINESS WIRE)--THERAPEUTICSMD, INC. (THERAPEUTICSMD OR THE COMPANY) (NASDAQ: TXMD), A COMPANY THAT OWNS RIGHTS TO PHARMACEUTICAL ROYALTIES, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2023. THE COMPANY'S TRANSFORMATION INTO A ROYALTY-BASED BUSINESS IS ONGOING. AS WE PHASE OUT OUR HISTORICAL BUSINESS OPERATIONS, WE REMAIN FOCUSED ON REDUCING COSTS AND CONSERVING CASH, STATED MARLAN D. WALKER, CHIEF EXECUTIVE OFFICER OF THERAPEUTICSMD. SECOND Q.

THERAPEUTICSMD ANNOUNCES SECOND QUARTER 2023 FINANCIAL RESULTS

BOCA RATON, FLA.--(BUSINESS WIRE)--THERAPEUTICSMD, INC. (THERAPEUTICSMD OR THE COMPANY) (NASDAQ: TXMD), A COMPANY THAT OWNS RIGHTS TO PHARMACEUTICAL ROYALTIES, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2023. FIRST QUARTER 2023 FINANCIAL RESULTS NET LOSS FROM CONTINUING OPERATIONS NET LOSS FROM CONTINUING OPERATIONS WAS $2.3 MILLION FOR THE QUARTER ENDED MARCH 31, 2023, OR $0.24 PER BASIC AND DILUTED COMMON SHARE, COMPARED TO A NET LOSS FROM CONTINUING OPERATIONS OF $17.9 MILLION, OR $2.08 PER BASIC AND DILUTED COMMON SHARE, FOR THE COMPARABLE PERIOD IN 2022. LICENSE AND SERVICE REVENUES FROM CONTINUING OPERATIONS LICENSE AND SERVICE REVENUES FROM CONTINUING OPERATIONS, WHICH ARE REVENUES RELATED TO LICENSE AGREEMENTS, WERE $0.4 MILLION FOR THE QUARTER ENDED MARCH 31, 2023, COMPARED TO $0.7 MILLION IN LICENSE AND SERVICE REVENUE RELATED TO SALES TO OTHER LICENSEES FOR THE FIRST QUARTER OF 2022. THIS DECREASE WAS DUE TO A DECREASE IN SALES TO LICENSEES AS A RESULT OF THE COMPANYS TRANSFORMATION AND TRANSITION FROM A MANUFACTURING AND COMMERCIALIZATION BUSINESS TO A ROYALTY-BASED BUSINESS, PARTIALLY OFFSET BY THE LICENSE REVENUE RECOGNIZED DURING THE FIRST QUARTER FROM THE MAYNE LICENSE AGREEMENT. TOTAL OPERATING EXPENSES FROM CONTINUING OPERATIONS TOTAL OPERATING EXPENSES FROM CONTINUING OPERATIONS FOR THE FIRST QUARTER OF 2023 WERE $3.1 MILLION, A DECREASE OF $14.8 MILLION, OR 82.8%, COMPARED TO THE FIRST QUARTER OF 2022. THIS DECREASE WAS DUE TO THE TRANSITION OF OUR BUSINESS FROM A MANUFACTURING AND COMMERCIALIZATION BUSINESS TO A ROYALTY-BASED BUSINESS WITH LIMITED INFRASTRUCTURE. DISCONTINUED OPERATIONS NET LOSS FROM DISCONTINUED OPERATIONS WAS $1.3 MILLION FOR THE QUARTER ENDED MARCH 31, 2023, OR $0.13 PER BASIC AND DILUTED COMMON SHARE, COMPARED TO A NET LOSS FROM DISCONTINUED OPERATIONS OF $31.1 MILLION, OR $3.62 PER BASIC AND DILUTED COMMON SHARE, FOR THE COMPARABLE PERIOD IN 2022. THE COMPANY CONTINUES TO WIND DOWN ITS FORMER COM

THERAPEUTICSMD ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS

BOCA RATON, FLA.--(BUSINESS WIRE)--THERAPEUTICSMD, INC. (THERAPEUTICSMD OR THE COMPANY) (NASDAQ: TXMD), A COMPANY THAT OWNS RIGHTS TO PHARMACEUTICAL ROYALTIES, TODAY REPORTED FINANCIAL RESULTS FOR THE FULL YEAR ENDED DECEMBER 31, 2022. AS A RESULT OF THE TRANSACTION WITH MAYNE PHARMA GROUP LIMITED (ASX: MYX) (MAYNE PHARMA) THAT CLOSED AT YEAR-END, IN WHICH THERAPEUTICSMD GRANTED MAYNE PHARMA AN EXCLUSIVE LICENSE TO COMMERCIALIZE THERAPEUTICSMDS PRODUCTS IN THE UNITED STATES, WE REPAID OUR DEBT, REDEEMED OUR OUTSTANDING PREFERRED STOCK, ELIMINATED OUR COMMERCIAL AND MANUFACTURING INFRASTRUCTURE, AND DOWNSIZED OUR REMAINING OPERATIONS, SAID MARLAN D. WALKER, CHIEF EXECUTIVE OFFICER OF THERAPEUTICSMD. WE LOOK FORWARD TO CONTINUING TO STREAMLINE OUR OPERATIONS AS WE COMPLETE THE TRANSITION TO A VIRTUAL BUSINESS MODEL THAT COLLECTS ROYALTIES FROM MAYNE PHARMA AND OUR OTHER LICENSEES. WE ALSO INTEND TO EXPLORE OTHER STRATEGIC PATHWAYS TO CREATE VALUE FOR THERAPEUTICSMD SHAREHOLDERS, SAID MR. WALKER. NET INCOME (LOSS) FROM CONTINUING OPERATIONS NET INCOME FROM CONTINUING OPERATIONS WAS $1.1 MILLION FOR THE YEAR ENDED DECEMBER 31, 2022, OR $0.12 PER BASIC SHARE, COMPARED TO A NET LOSS OF $79.3 MILLION, OR $9.96 PER BASIC SHARE, FOR 2021. THE INCREASE IN NET INCOME WAS A RESULT OF AN INCREASE IN LICENSE REVENUE DUE TO THE MAYNE PHARMA TRANSACTION. LICENSE REVENUES FROM CONTINUING OPERATIONS LICENSE REVENUES FROM CONTINUING OPERATIONS, WHICH ARE REVENUES FROM CONTINUING OPERATIONS RELATED TO LICENSE AGREEMENTS, WERE $70.0 MILLION FOR THE YEAR ENDED DECEMBER 31, 2022, COMPARED TO $2.6 MILLION FOR 2021. THE INCREASE IN LICENSE REVENUES WAS A RESULT OF THE ALLOCATION OF THE INITIAL UPFRONT PAYMENT AND GUARANTEED MINIMUM ROYALTIES FROM MAYNE PHARMA. TOTAL OPERATING EXPENSES FROM CONTINUING OPERATIONS TOTAL OPERATING EXPENSES FROM CONTINUING OPERATIONS FOR 2022 WERE $67.4 MILLION COMPARED TO $80.7 MILLION FOR 2021. TOTAL OPERATING EXPENSES FROM CONTINUING OPERATIONS FOR 2022 INCLU

THERAPEUTICSMD ANNOUNCES FULL YEAR 2022 FINANCIAL RESULTS AND PROVIDES UPDATE ON BUSINESS MODEL TRANSITION

BOCA RATON, FLA.--(BUSINESS WIRE)--THERAPEUTICSMD, INC. (NASDAQ: TXMD) (THERAPEUTICSMD, TXMD OR THE COMPANY), AN INNOVATIVE, LEADING WOMENS HEALTHCARE COMPANY, TODAY ANNOUNCED THAT IT HAS COMPLETED ITS PREVIOUSLY ANNOUNCED TRANSACTION WITH MAYNE PHARMA GROUP LIMITED (MAYNE PHARMA), AN ASX-LISTED SPECIALTY PHARMACEUTICAL COMPANY FOCUSED ON COMMERCIALIZING NOVEL AND GENERIC PHARMACEUTICALS, PURSUANT TO WHICH TXMD GRANTED MAYNE PHARMA AN EXCLUSIVE LICENSE TO COMMERCIALIZE TXMDS PRODUCTS IN THE UNITED STATES. IN ADDITION, TXMD SOLD CERTAIN ASSETS TO MAYNE PHARMA TO ENABLE IT TO COMMERCIALIZE THE PRODUCTS. TOTAL CONSIDERATION PAID TO TXMD INCLUDED AN UPFRONT CASH PAYMENT OF $140.0 MILLION FOR THE LICENSE GRANT AND SALE OF CERTAIN ASSETS, PLUS AN ADDITIONAL APPROXIMATELY $13.1 MILLION FOR THE ACQUISITION OF NET WORKING CAPITAL AND PREPAID ROYALTIES. IN ADDITION, TXMD IS ELIGIBLE TO RECEIVE UP TO $30.0 MILLION IN MILESTONE PAYMENTS AS WELL AS ROYALTIES ON NET SALES OF BETWEEN 7.5% AND 8.0%, FOR A PERIOD OF 20 YEARS, WITH MINIMUM ANNUAL ROYALTIES OF $3.0 MILLION PER YEAR FOR 12 YEARS, ADJUSTED FOR INFLATION AT AN ANNUAL RATE OF 3%, SUBJECT TO CERTAIN FURTHER ADJUSTMENTS. THE APPROXIMATELY $1.0 MILLION IN PREPAID ROYALTIES PAID AT CLOSING WILL REDUCE THE FIRST FOUR QUARTERLY ROYALTY PAYMENTS THAT WOULD HAVE OTHERWISE BEEN PAYABLE TO TXMD. THE COMPANY USED A PORTION OF THE PROCEEDS TO REPAY ALL OBLIGATIONS UNDER THE COMPANYS FINANCING AGREEMENT WITH SIXTH STREET SPECIALTY LENDING, INC. IN ADDITION, THE COMPANY ALSO REDEEMED ALL 29,000 OUTSTANDING SHARES OF ITS SERIES A PREFERRED STOCK AT A PURCHASE PRICE OF $1,333 PER SHARE AND PAID CERTAIN AFFILIATES OF RUBRIC CAPITAL MANAGEMENT LP (RUBRIC) APPROXIMATELY $3.0 MILLION AS A MAKE-WHOLE PAYMENT PURSUANT TO THE SUBSCRIPTION AGREEMENTS PREVIOUSLY ENTERED INTO BETWEEN THE COMPANY AND RUBRIC. "WE ARE PLEASED TO HAVE COMPLETED THIS TRANSACTION WITH MAYNE PHARMA, WHICH ENABLED US TO REPAY OUR DEBT, REDEEM OUR PREFERRED STOCK AND PROVI

TherapeuticsMD, Inc.

TXMD

Price

Financials Overview

Financial Reports

No items found.

Press Releases

TherapeuticsMD, Inc.

TXMD.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

TXMD